Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 310.9% in June

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 137,273 shares, a growth of 310.9% from the June 15th total of 33,404 shares. Approximately 24.6% of the company’s shares are sold short. Based on an average daily volume of 4,260,794 shares, the days-to-cover ratio is currently 0.0 days.

Insider Activity

In related news, major shareholder Financial Lp Hrt acquired 8,266 shares of Shuttle Pharmaceuticals stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average cost of $3.38 per share, for a total transaction of $27,939.08. Following the acquisition, the insider owned 60,540 shares in the company, valued at approximately $204,625.20. This represents a 15.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 53,398 shares of company stock worth $181,764 and sold 38,133 shares worth $132,128. Insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SHPH. Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Boothbay Fund Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at about $37,000. Ikarian Capital LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the third quarter worth about $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Analyst Upgrades and Downgrades

SHPH has been the topic of several recent analyst reports. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Shuttle Pharmaceuticals currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Stock Up 1.4%

SHPH traded up $0.04 on Monday, reaching $2.96. The company had a trading volume of 12,456,514 shares, compared to its average volume of 2,341,409. Shuttle Pharmaceuticals has a 1 year low of $2.71 and a 1 year high of $55.90. The stock has a market capitalization of $1.89 million, a PE ratio of -0.06 and a beta of 0.29. The stock has a 50-day moving average price of $4.86 and a 200-day moving average price of $9.96.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .